Published in Oncology (Williston Park) on July 01, 1987
CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol (2014) 0.84
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst (1989) 2.58
Safety and activity of saquinavir in HIV infection. Lancet (1995) 2.32
Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ (2001) 2.01
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Effect of phospholipase C-gamma overexpression on PDGF-induced second messengers and mitogenesis. Science (1990) 1.87
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin Pharmacol Ther (1976) 1.39
Ethics and pharmaceutical medicine -- the full report of the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract (2006) 1.34
Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab (1985) 1.29
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
Guiding Principles for Pharmaceutical Physicians from the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract (2006) 1.25
Stimulation of healing of varicose ulcers by ultrasound. Ultrasonics (1976) 1.22
Methodology for the assessment of new dichotomous diagnostic tests. J Chronic Dis (1981) 1.16
The cardiotoxicity of anticancer agents. Semin Oncol (1982) 1.15
Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother (1997) 1.09
Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg (1980) 1.08
Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women. Eur J Cancer (1973) 0.98
hUBC9 associates with MEKK1 and type I TNF-alpha receptor and stimulates NFkappaB activity. FEBS Lett (1998) 0.95
Long-term survivors with small cell carcinoma of the lung. Eur J Cancer (1980) 0.95
The role of antitumor antibiotics in current oncologic practice. Cancer Chemother Pharmacol (1978) 0.95
The use of peritoneoscopy in the detection of liver metastases. Cancer (1978) 0.93
The chemotherapy of Hodgkin's disease: past experiences and future directions. Cancer (1978) 0.93
Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis (1994) 0.93
Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol (1989) 0.93
Carboplatin: current status and future prospects. Cancer Treat Rev (1988) 0.91
Overview of Taxol safety. J Natl Cancer Inst Monogr (1993) 0.91
Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res (1998) 0.90
Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol (1983) 0.89
Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis (1990) 0.89
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol (2014) 0.89
Design and implementation of the stavudine parallel-track program. J Infect Dis (1995) 0.89
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Ann Intern Med (1995) 0.88
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol (1979) 0.88
Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep (1983) 0.88
VM 26 and VP 16-213: a comparative analysis. Cancer (1977) 0.88
Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials (1981) 0.87
cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity. Adv Pharmacol Chemother (1979) 0.87
Anthracycline derivatives in new drug development programs. Cancer Treat Rep (1979) 0.86
m-AMSA and PALA: two new agents in cancer chemotherapy. Cancer Chemother Pharmacol (1979) 0.86
Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw (1994) 0.85
In vitro growth of human malignancies in a cloning assay. Recent Results Cancer Res (1984) 0.85
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. Ann Intern Med (1994) 0.85
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. J Clin Oncol (1984) 0.84
EORTC randomized trial for the adjuvant therapy of T1 bladder carcinoma. Eur Urol (1976) 0.84
Daunomycin: an anthracycline antibiotic effective in acute leukemia. Adv Pharmacol Chemother (1978) 0.83
Chemotherapy of testicular cancer: from palliation to curative adjuvant therapy. Semin Oncol (1979) 0.83
Tuftsin - unimportant or forgotten. N Engl J Med (1977) 0.83
Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol (1988) 0.82
Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ (2010) 0.82
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. Cancer Treat Rep (1977) 0.82
Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol (1981) 0.81
Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. Eur J Cancer Clin Oncol (1984) 0.81
Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex. Clin Infect Dis (1993) 0.81
In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer (1994) 0.80
Overview of hormonal therapy in advanced breast cancer. Semin Oncol (1990) 0.80
Preventing petrol sniffing in Aboriginal communities. Community Health Stud (1989) 0.80
Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. Cancer Chemother Pharmacol (1990) 0.80
Phase II study of tallysomycin S10b in patients with advanced head and neck cancer. Invest New Drugs (1990) 0.79
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program. J Acquir Immune Defic Syndr (1994) 0.78
Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck. Cancer (1984) 0.78
Phase II study of carminomycin in a human tumor cloning assay. Invest New Drugs (1984) 0.78
Chemotherapy principles in the treatment of prostatic cancer. Prostate (1984) 0.78
Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment. J Endocrinol (1977) 0.78
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antivir Ther (1996) 0.78
Phase II study of ametantrone in a human tumor cloning assay. Eur J Cancer Clin Oncol (1985) 0.78
Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC Breast Cancer Cooperative Group. Eur J Cancer Clin Oncol (1985) 0.78
Drug discovery and development in the pharmaceutical industry. Semin Oncol (1992) 0.78
Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol (1987) 0.78
Interleukin-2 therapy for refractory and relapsing lymphomas. Eur J Cancer (1991) 0.77
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside. Cancer Chemother Pharmacol (1986) 0.77
Phase II study of 9-hydroxy-2N-methylellipticinium acetate. Eur J Cancer Clin Oncol (1984) 0.77
Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Invest New Drugs (1985) 0.77
Megestrol acetate: clinical experience. Cancer Treat Rev (1989) 0.77
Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule. Eur J Cancer Clin Oncol (1982) 0.77
Neocarzinostatin (NSC 157365) a new cancerostatic compound. Oncology (1976) 0.77
N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer Clin Oncol (1982) 0.77
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group. Eur J Cancer Clin Oncol (1982) 0.76
Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue. Biochem Biophys Res Commun (1998) 0.76
Validation of the clinical predictive values of the in vitro phase II clonogenic assay in cancer of the breast and ovary. Am J Clin Oncol (1987) 0.76
Clinical implications of cisplatin pharmacology. Recent Results Cancer Res (1980) 0.76
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antivir Ther (1997) 0.76
N-(Phosphonacetyl)-L-aspartate (PALA): current status. Recent Results Cancer Res (1980) 0.76
Current cooperative clinical trials in the non-Hodgkin's lymphomas. Cancer Treat Rep (1977) 0.76
Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood (1992) 0.76
Estramustine phosphate: a specific chemotherapeutic agent?. J Urol (1977) 0.76
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol (1986) 0.75
Letter: Breast cancer regression under oestrogen therapy. Br Med J (1974) 0.75
Time relationship between last dose of daunorubicin and congestive heart failure. Cancer Treat Rep (1977) 0.75
Emerging proteinase inhibitors. Lancet (1995) 0.75
EORTC phase II trial of vindesine in advanced melanoma. Eur J Cancer Clin Oncol (1983) 0.75
[Chemotherapy of solid tumors. The role of cisplatin in today's chemotherapy]. Rev Med Brux (1983) 0.75
Phase I trial with 4'-deoxydoxorubicin (esorubicin). Invest New Drugs (1983) 0.75
[Phase I study of alizapride in cancer patients treated with cisplatin]. Sem Hop (1983) 0.75